At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.
株式会社ビーフソムリエ(本社:東京都品川区、代表取締役社長:松岡俊樹)は、2025年6月18日に札幌で開催された「The JSSA Sapporo Pitch Award & Power Matching Booth Vol.60」において、ファイナリスト6...
株式会社ビーフソムリエ(本社:東京都品川区、以下:ビーフソムリエ)は、世界で一番ブランド牛に詳しくなるために、「牛肉テロワールプロジェクト」を完成させる取り組みを続けていきます。世界中の牛肉を、産...
株式会社ビーフソムリエ(以下「ビーフソムリエ」、東京都品川区、代表取締役社長: 松岡俊樹)は、一般社団法人AgVenture Lab(以下「あぐラボ」、東京都千代田区、代表理事理事長: 荻野浩輝)より資金調達を行い...
データサイエンスの力で豊かな食文化を育む、をパーパスに掲げる株式会社ビーフソムリエ(本社:東京都品川区、代表取締役社長:松岡俊樹)は、"誰もが温かく繋がるカフェ" SY.ノートCafe とともに、親子で楽しめ...
[画像1: https://prtimes.jp/i/154461/1/resize/d154461-1-8b0038abb83e6bd627d5-6.jpg ] 近畿大学生物理工学部(和歌山県紀の川市)遺伝子工学科教授 松本和也は、肉用牛の将来の肉質等を採⾎検査によって可視化...

By utilizing DNA as a functional organic material, we are developing a “DNA linker technology” that enables precise conjugation of antibodies with drugs and functional molecules, alongside related applications such as cell adhesion and enzyme-free nucleic acid detection. Our unique molecular design enhances the performance and multifunctionality of diverse materials, establishing foundational technologies for ADC drug development, 3D cell models, and diagnostic platforms. Furthermore, we expand these technologies into research support and collaborative R&D to accelerate industrial application and societal implementation.

A startup that synthesizes long, complex DNA using proprietary technology, enabling the flexible design of diverse gene combinations. It also provides comprehensive support from development to manufacturing processes for viral vectors and mRNA required for gene therapy.

A drug discovery venture tackling next-generation cancer treatment using marine-derived compounds that improve tumor hypoxia while minimizing side effects. Already commercialized as veterinary medicine, it supports the lives of both humans and pets.

A startup developing artificial red blood cells coated with a lipid bilayer. These cells possess oxygen-carrying capacity equivalent to red blood cells and enable long-term storage, aiming to revolutionize transfusion medicine through stable blood transfusions in veterinary medicine and future practical application in human healthcare.